Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Christophe Borg

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2167-1458; OpenAlex author ID A5022288769. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
48
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: none · 2019: none · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 3 papers

Papers 12

  1. CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy. Co-author DOI 10.1080/2162402x.2023.2294563↗
  2. A comparison of target volumes drawn on arterial and venous phase scans during radiation therapy planning for patients with pancreatic cancer: the PANCRINJ stu… Co-author DOI 10.1186/s13014-024-02477-8↗
  3. Deep Multiple Instance Learning Model to Predict Outcome of Pancreatic Cancer Following Surgery. Co-author DOI 10.3390/biomedicines12122754↗
  4. SALL4-related gene signature defines a specific stromal subset of pancreatic ductal adenocarcinoma with poor prognostic features. Last author DOI 10.1002/1878-0261.13370↗
  5. Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: A French comprehensive multicentre ambispective obs… Co-author DOI 10.1016/j.ejca.2022.01.040↗
  6. Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.683289↗
  7. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. Co-author DOI 10.1016/s2468-1253(19)30327-9↗
  8. FOLFIRINOX De-Escalation in Advanced Pancreatic Cancer: A Multicenter Real-Life Study. Co-author DOI 10.1634/theoncologist.2020-0577↗
  9. FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study. Co-author DOI 10.4251/wjgo.v12.i3.332↗
  10. A systematic review of economic evaluation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2017.08.035↗
  11. Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1093/jnci/djx037↗
  12. Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a mu… Last author DOI 10.1186/s12885-016-2860-6↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Angélique Vienot · 8 shared papers, 2017–2024 · strength 0.97
  2. Déwi Vernerey · 6 shared papers, 2016–2024 · strength 0.63
  3. Caroline Truntzer · 3 shared papers, 2023–2024 · strength 0.54
  4. François Ghiringhelli · 3 shared papers, 2023–2024 · strength 0.54
  5. Christelle d’Engremont · 5 shared papers, 2016–2022 · strength 0.42
  6. Anthony Turpin · 3 shared papers, 2020–2022 · strength 0.30
  7. Fabien Zaidi · 1 shared paper, 2024 · strength 0.22
  8. Jihane Boustani · 1 shared paper, 2024 · strength 0.22
  9. Coralie Schoumacher · 1 shared paper, 2024 · strength 0.20
  10. Hortense Chevalier · 2 shared papers, 2020 · strength 0.19
  11. Pascal R. Hammel · 2 shared papers, 2020 · strength 0.19
  12. Olivier Bouché · 2 shared papers, 2017–2022 · strength 0.16
  13. Gerlinde Avérous · 1 shared paper, 2023 · strength 0.16
  14. Cindy Neuzillet · 2 shared papers, 2017–2020 · strength 0.16
  15. Frédéric Di Fiore · 1 shared paper, 2022 · strength 0.11
  16. Gaël S. Roth · 1 shared paper, 2022 · strength 0.11
  17. Tullio Piardi · 1 shared paper, 2022 · strength 0.11
  18. Lilian Schwarz · 1 shared paper, 2022 · strength 0.11
  19. Mathias Brügel · 1 shared paper, 2022 · strength 0.11
  20. Mehdi El Amrani · 1 shared paper, 2022 · strength 0.11
  21. Stéphanie Truant · 1 shared paper, 2022 · strength 0.11
  22. Alexandre Doussot · 1 shared paper, 2022 · strength 0.11
  23. Camille Evrard · 1 shared paper, 2022 · strength 0.11
  24. Aurélien Lambert · 1 shared paper, 2022 · strength 0.11
  25. Nicolas Williet · 1 shared paper, 2022 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.